Sponsor & Developer Portfolio
Serum Institute of India
Clinical development pipeline, platform architecture, and registered trial tracking for Serum Institute of India vaccine candidates.
5
Candidates
4
Target Diseases
5
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 2 Discontinued / Inactive: 1 Phase 2 Clinical Trial: 1 Phase 1 Clinical Trial: 1
Platform Technologies
Protein / subunit: 3 Biological (unspecified platform): 2
Target Pathogens & Indications
HPV Hib Malaria Polio
Vaccine Pipeline Candidates (5)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-dtp-hb-hib-vaccine-serum-institute-of-india-pvt-ltd
DTP-HB-Hib vaccine
Target: Hib
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2016-02 (registry estimate)
Phase 1 Clinical Trial
ctgov-recombinant-poliomyelitis-vaccine-rpv-serum-institute-of-india-p
Recombinant Poliomyelitis Vaccine (rPV)
Target: Polio
Platform: Protein / subunit
Key Milestone: Primary completion (most advanced trial): 2026-11 (registry estimate)
Phase 2 Clinical Trial
ctgov-10-g-of-r21-with-50-g-matrix-m1-serum-institute-of-india-pvt-ltd
RABIVAX-S
Target: Malaria
Platform: Protein / subunit
Key Milestone: Primary completion (most advanced trial): 2027-11 (registry estimate)
Phase 3 Clinical Trial
ctgov-2-doses-of-vaccine-quadrivalent-recombinant-human-papillomavirus
2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
Target: HPV
Platform: Protein / subunit
Key Milestone: Primary completion (most advanced trial): 2032-07 (registry estimate)
Phase 3 Clinical Trial
ctgov-cervavac-as-three-dose-regimen-serum-institute-of-india-pvt-ltd
Cervavac as two dose regimen
Target: HPV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-12-31 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.